|Articles|December 1, 2010

'DTS' deemed more accurate term

Several algorithms help physicians base appropriate therapy on signs and symptons

Newsletter

Don’t miss out—get OT Europe updates delivered straight to your inbox.

Subscribe

Related Content

Synthetic corneal implant shows promise in eyes with chronic corneal oedema

ByOphthalmology Times Europe Staff

July 4th 2026

How the ocular microbiome may shape outcomes in keratoplasty

ByOphthalmology Times Europe Staff

July 2nd 2026

Piotr A. Woźniak, MD, PhD | Ophthalmology Times Europe

European Dry Eye Society Congress 2026: real-world evidence on Artelac Complete in dry eye disease

ByPiotr A. Woźniak, MD, PhD,Lucia Gambuzza

June 24th 2026

The real cost of persistent epithelial defects: Lessons from an NHS audit

ByOphthalmology Times Europe Staff

June 19th 2026

Time is vision: Act fast after ocular chemical burns

By Hajirah N. Saeed, MD, MPH

June 16th 2026

Latest CME

Video

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Neel Pasricha, MD; Asim V. Farooq, MD; Susana Campos, MD, MPH

Video

Treatment Optimization in the Evolving Anti-VEGF Era

Carl Danzig, MD, FASRS; Sruthi Arepalli, MD; Priya Vakharia, MD, FASRS

Video

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

'DTS' deemed more accurate term

Related Content

Synthetic corneal implant shows promise in eyes with chronic corneal oedema

How the ocular microbiome may shape outcomes in keratoplasty

European Dry Eye Society Congress 2026: real-world evidence on Artelac Complete in dry eye disease

The real cost of persistent epithelial defects: Lessons from an NHS audit

Time is vision: Act fast after ocular chemical burns

Latest CME

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Treatment Optimization in the Evolving Anti-VEGF Era

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Trending on Eye Care Network - Ophthalmology Times

Retinal imaging as a window into atrial fibrillation

OCT-980 receives FDA orphan drug designation for retinitis pigmentosa

First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP

The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD

Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery